EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children



Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children



Microbial Drug Resistance 21(2): 244-251



This retrospective study was conducted to evaluate clinical outcomes of bacteremia caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae and their antibiotic susceptibilities in febrile neutropenic children. Clinical characteristics, prognosis, and antibiotic susceptibilities were reviewed and compared between febrile neutropenic children with bacteremia caused by ESBL-producing and non-ESBL-producing E. coli and K. pneumoniae. A total of 61 episodes of E. coli and K. pneumoniae bacteremia, including 21 episodes (34.4%) due to ESBL-producing strains, were diagnosed. There was no significant factor associated with bacteremia by ESBL-producing strains. Empirical antibiotics were appropriate in 85.7% of the ESBL group and 95.0% of the non-ESBL group. In the entire study population, seven deaths (11.5%), including three deaths (4.9%) due to E. coli and K. pneumoniae bacteremia, occurred. The complication and mortality rates were not significantly different between the two groups. Antibiotic susceptibility rates were significantly lower in the ESBL group than in the non-ESBL group in most antibiotics. Although 52.4% and 66.7% of the ESBL-producing isolates were susceptible to piperacillin/tazobactam and cefepime, respectively, 96.7% of all the isolates and 90.5% of the ESBL-producing isolates were susceptible to piperacillin/tazobactam or cefepime in combination with aminoglycoside. In conclusion, the ESBL group did not show a significantly unfavorable outcome, and empirical therapy with piperacillin/tazobactam or cefepime in combination with aminoglycoside might be more useful for febrile neutropenic children, instead of β-lactam monotherapy in institutions with high prevalence of ESBL-producing E. coli and K. pneumoniae.

(PDF emailed within 0-6 h: $19.90)

Accession: 053162040

Download citation: RISBibTeXText

PMID: 25398058

DOI: 10.1089/mdr.2014.0092



Related references

Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome. Annals of Hematology 92(4): 533-541, 2013

Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae. Diagnostic Microbiology and Infectious Disease 70(1): 150-153, 2011

Treatment outcome of extended-spectrum B-lactamase producing Escherichia coli and Klebsiella pneumoniae bacteremia. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 37: 289, 1997

Risk factors and outcome in extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bacteremia. Saudi Medical Journal 30(10): 1366-7; Author Reply1366-7, 2010

Clinical outcome of patients with extended-spectrum beta-lactamase -producing Klebsiella pneumoniae and Escherichia coli bacteremia after treatment with expanded-spectrum cephalosporins. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 39: 166, 1999

Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility. Antimicrobial Agents and ChemoTherapy 56(6): 2888-2893, 2012

Risk factors for 28-day mortality in elderly patients with extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae bacteremia. Archives of Gerontology and Geriatrics 58(1): 105-109, 2014

Carbapenem Therapy for Bacteremia Due to Extended-Spectrum-beta-Lactamase-Producing Escherichia coli or Klebsiella pneumoniae Implications of Ertapenem Susceptibility. 2012

Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Journal of Infection 64(5): 533-534, 2012

Risk factors for multidrug resistance in nosocomial bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Microbial Drug Resistance 18(5): 518-524, 2013

Clinical manifestations and prognostic factors in cancer patients with bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae. Journal of Microbiology, Immunology, and Infection 44(4): 282-288, 2011

Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. Bmc Research Notes 3(): 116-116, 2010

Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. Antimicrobial Agents and ChemoTherapy 51(4): 1481-1486, 2007

Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Annals of Hematology 91(1): 115-121, 2012

Extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bacteremia. Risk factors and outcome in the eastern region of Saudi Arabia. Saudi Medical Journal 30(6): 803-808, 2009